Boston Scientific announced FDA approval of its Innova Vascular Self-Expanding Stent System for treating peripheral artery disease. The device was approved via the agency's stringent PMA pathway for high-risk, innovative devices.
Medical device titan Boston Scientific is jumping into heart diagnostics, announcing that it will become a "significant shareholder" in cardiology-related diagnostic and monitoring tech company Preventice Solutions.
Having an edge in cardiac monitoring tech can translate into sales of interventional cardiac devices down the line. That's a strategy that med tech behemoth Medtronic is adhering to, as is its competitor Boston Scientific. The latter has disclosed a partnership with Preventice Solutions to exclusively market its cardiology-related diagnostic and monitoring products worldwide, although financial details weren't released.
Boston Scientific representatives provided updates on their recent product launches during the company's Q2 2015 earnings call. New Boston Scientific devices on the market include the latest generation of its S-ICD subcutaneous implantable defibrillator, SpyGlass DS endoscope, NOVI spinal cord stimulation system and the Watchman to prevent stroke.
Boston Scientific had high hopes for its electrode-tipped catheter treatment for asthma after snatching up the system in 2010 through its $193.5 million purchase of Asthmatx. But the company is hitting a wall with the product as insurers question the treatment's cost-effectiveness and safety.
Boston Scientific has started a study of its first resorbable, drug-eluting scaffold system to treat atherosclerotic coronary lesions. It incorporates aspects of the company's Synergy System, which has a resorbable polymer and everolimus drug-coating, that the device maker expects will be approved by the FDA during the fourth quarter.
A meta-analysis of the data surrounding Boston Scientific's recently approved stroke-preventing Watchman device concluded that it reduces risk of death from hemorrhagic stroke, cardiovascular death, and major non–procedural-related bleeding compared to patients on long-term use of the blood thinner warfarin.
Boston Scientific promoted new information that its latest spinal cord stimulator is twice as effective as its predecessor at lower back pain relief at the International Neuromodulation Society 12th World Congress in Montreal.
Boston Scientific was ordered to fork over $100 million to a woman who alleged the company's vaginal mesh products caused her undue pain and suffering, a stinging blow for the device giant as it moves to settle claims with patients.
Irish researchers have developed a gel containing clusters of pancreatic cells that they say can control glucose levels for up to 5 years when administered via a minimally invasive injection procedure being developed by medical device bigwig Boston Scientific.